The metabolic syndrome: Review;Metabolik sendrom

Turkiye Klinikleri Journal of Medical Sciences

Volumn 28, Issue 5, 2008, Pages 686-696

  Gören, Başak ^a   Fen, Turgay ^b  

^a Dahiliye Klinigi   (Turkey)

^b Dr Abdurahman Yurtarslan Ankara Onkoloji E itim ve Ara tirma Hastanesi   (Turkey)

Author keywords

Coronary arteriosclerosis; Insulin resistance; Metabolic syndrome X

Indexed keywords

CARBOHYDRATE; FAT; GLUCOSE; INSULIN; PROTEIN;

BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; ENERGY METABOLISM; FIBRINOLYSIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HEREDITY; HIGH RISK PATIENT; HORMONE ACTION; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; REVIEW; TREATMENT PLANNING; VASCULAR DISEASE; VASCULITIS;

EID: 54349084287     PISSN: 13000292     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care 2003;26:1297-303.
2. Marks V. The metabolic syndrome. Nurs Stand 2003;17:37-44.
3. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000;106:171-6.
4. Gerich JE, Dailey G. Advances in diabetes for the millennium: understanding insulin resistance. MedGenMed 2004;6(3 Suppl):11.
5. Lautt WW, Macedo MP, Sadri P, Legare DJ, Reid MA, Guarino MP. Pharmaceutical reversal of insulin resistance. Proc West Pharmacol Soc 2004;47:30-2.
6. Poulsen P, Levin K, Petersen I, Christensen K, Beek-Nielsen H, Vaag A. Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes 2005;54:275-83.
7. Bohlooly-Y M, Olsson B, Bruder CE, Lindén D, Sjögren K, Bjursell M, et al. Growth hormone overexpression in the central nervous system results in hyperphagia-induced obesity associated with insulin resistance and dyslipidemia. Diabetes 2005;54:51-62.
8. Vaccaro O, Masulli M, Cuomo V, Rivellese AA, Uusitupa M, Vessby B, et al. Comparative evaluation of simple indices of insulin resistance. Metabolism 2004;53:1522-6.
9. Puljak L, Pagliassotti MJ, Wei Y, Qadri I, Parameswara V, Esser V, et al. Inhibition of cellular responses to insulin in a rat liver cell line. A role for PKC in insulin resistance. J Physiol 2005;563(Pt 2):471-82.
10. Reid MA, Lautt WW. Pattern of insulin delivery affects hepatic insulin sensitizing substance (HISS) action and insulin resistance. Can J Physiol Pharmacol 2004;82:1068-74.
11. Ahrén B, Pacini G. Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes Obes Metab 2005; 7:2-8.
12. Wittmann I, Soltész G, Jermendy G, Nagy J. [Decreased first-phase secretion of insulin may play a role in the development of insulin resistance] Orv Hetil 2004;145:2267-72.
13. Axelsson 3, Heimbürger O, Lindholm B, Stenvinkel P. Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr 2005;15:131-6.
14. Danielsson A, Ost A, Lystedt E, Kjolhede P, Gustavsson J, Nystrom FH, et al. Insulin resistance in human adipocytes occurs downstream of IRS1 after surgical cell isolation but at the level of phosphorylation of IRS1 in type 2 diabetes. FEBS J 2005;272:141-51.
15. Chan DC, Watts GF, Ng TW, Uchida Y, Sakai N, Yamashita S, et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem 2005;51:578-85.
16. Chiasson JL, Rabasa-Lhoret R. Prevention of type 2 diabetes: insulin resistance and beta-cell function. Diabetes 2004;53(Suppl 3):S34-8.
17. Ortega-González C, Luna S, Hernández L, Crespo G, Aguayo P, Arteaga-Troncoso, G, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1360-5.
18. Haffner SM, D'Agostino R, Saad MF, Rewers M, Mykkänen L, Selby J, et al. Increased insulin resistance and insulin secretion in non-diabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Diabetes 1996;45:742-8.
19. Taylor SI. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992;41:1473-90.
20. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004;44:2293-300.
21. Rask-Madsen C, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 2005;25:487-96.
22. Bell DS. Advances in diabetes for the millennium: the heart and diabetes. MedGenMed 2004;6(3 Suppl):7.
23. Inchiostro S. Measurement of insulin sensitivity in Type 2 diabetes mellitus: comparison between KITT and HOMA-%S indices and evaluation of their relationship with the components of the insulin resistance syndrome. Diabet Med 2005;22:39-44.
24. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic sub-clinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
25. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996;93:1809-17.
26. Muhammad S. Epidemiology of diabetes and obesity in the United States. Compend Contin Educ Dent 2004;25:195-8.
27. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163:427-36.
28. Kendall DM, Sobel BE, Coulston AM, Peters Harmel AL, McLean BK, Peragallo-Dittko V, et al. The insulin resistance syndrome and coronary artery disease. Coron Artery Dis 2003; 14:335-48.
29. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
30. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15: 539-53.
31. Tanaka A. Postprandial hyperlipidemia and atherosclerosis. J Atheroscler Thromb 2004; 11:322-9.
32. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997;46(Suppl 2):S9-13.
33. Desouza C, Pendergrass M, Fonseca V. The insulin resistance syndrome and its vascular complications. Am J Caridol 1999;32:16-20.
34. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
35. Turner R, Holman R, Stratton I, Cull C, Frighi V, Manley S, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998:317:703-12.
36. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
37. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
38. Arauz-Pacheco C, Parrott MA, Raskin P; American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26(Suppl 1):S80-2.
39. McFarlane SI, Sowers JR. Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J Clin Endocrinol Metab 2003;88:516-23.
40. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
41. Hori Y, Nakatani K, Morioka K, Katsuki A, Gabazza EC, Yano Y, et al. Insulin enhanced thrombin-activable fibrinolysis inhibitor expression through PI3 kinase/Akt pathway. Int J Mol Med 2005;15:265-8.
42. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998;47:290-3.
43. Hayes MG, Sobel BE, Taatjes DJ, Rincon M, Schneider DJ. Attenuation of migration of vascular smooth muscle cells by overexpression of plasminogen activator inhibitor type 1. J Am Coll Caridol 2002;39:203-5.
44. Vaughan DE. PAI-1 and cellular migration: dabbling in paradox. Arterioscler Thromb Vasc Biol 2002;22:1522-3.
45. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999;22:1971-7.
46. Bergenstal RM, Kendal DM, Franz MJ, Rubenstein AH. Management of type 2 diabetes: a systematic approach to meeting the standards of management education medical nutrition therapy and exercise. In: De Groot LJ, Jameson L, eds. Endocrinology. 4th ed. Philadelphia: WB Saunders Company; 2000. p.810-20.
47. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
48. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
49. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW; Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25:1845-50.
50. Smith DO, LeRoith D. Insulin resistance syndrome, pre-diabetes, and the prevention of type 2 diabetes mellitus. Clin Cornerstone 2004;6:7-6.
51. Ito H, Nakasuga K, Ohshima A, Maruyama T, Kaji Y, Harada M, et al. Detection of cardiovascular risk factors by indices of obesity obtained from anthropometry and dual-energy X-ray absorptiometry in Japanese individuals. Int J Obes Relat Metab Disord 2003;27:232-7.
52. Moreno LA, Pineda I, Rodríguez G, Fleta J, Sarría A, Bueno M. Waist circumference for the screening of the metabolic syndrome in children. Acta Paediatr 2002;91:1307-12.
53. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002;19:527-34.
54. Schwenke DC. Insulin resistance, low-fat diets, and low-carbohydrate diets: time to test new menus. Curr Opin Lipidol 2005;16:55-60.
55. Biolo G, Ciocchi B, Stulle M, Piccoli A, Lorenzon S, Dal Mas V, et al. Metabolic consequences of physical inactivity. J Ren Nutr 2005;15:49-53.
56. Muscelli E, Mingrone G, Camastra S, Manco M, Pereira JA, Pareja JC, et al. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med 2005;118:51-7.
57. Stewart KJ, Bacher AC, Turner K, Lim JG, Hees PS, Shapiro EP, et al. Exercise and risk factors associated with metabolic syndrome in older adults. Am J Prev Med 2005;28:9-18.
58. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metabolism 1990;39:905-12.
59. Pereira MA, Kartashov AI, Ebbeling CB, Van Horn L, Slattery ML, Jacobs DR Jr, et al. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet 2005;365:36-42.
60. Robinson LE, Graham TE. Metabolic syndrome, a cardiovascular disease risk factor: role of adipocytokines and impact of diet and physical activity. Can J Appl Physiol 2004;29:808-29.
61. Pyǒrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
62. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998;98: 2513-9.
63. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
64. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
65. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341: 410-8.
66. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162:2597-604.
67. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
68. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708-11.
69. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
70. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-61.
71. Jacob S, Henriksen EJ. Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome. J Clin Hypertens (Greenwich) 2004;6:690-6.
72. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
73. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43:993-1002.
74. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-7.
75. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004;30:487-96.
76. Gleiter CH, Jägle C, Gresser U, Mörike K. Candesartan. Cardiovasc Drug Rev 2004;22: 263-84.
77. Doggrell SA. Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy. Expert Opin Pharmacother 2002;3:625-8.
78. Suzuki K, Souda S, Ikarashi T, Kaneko S, Nakagawa O, Aizawa Y. Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy. Diabetes Res Clin Pract 2002;57:179-83.
79. Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004;15:3117-25.
80. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and iow-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
81. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33.
82. Kaufman FR. Type 2 diabetes mellitus in children and youth: a new epidemic. J Pediatr Endocrinol Metab 2002;15(Suppl 2):737-44.
83. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002;25:89-94.
84. Lebovitz HE. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes. Diabetes Care 1999;22 (Suppl 3):C41-4.
85. Del Prato S, Marchetti P. Targeting insulin resistance and beta-cell dysfunction: the role of thiazolidinediones. Diabetes Technol Ther 2004;6:719-31.
86. Hung YJ, Hsieh CH, Pei D, Kuo SW, Lee JT, Wu LY, et al. Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance. Clin Endocrinol (Oxf) 2005;62:85-91.